Navigation Links
Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
Date:7/30/2008

ents with heart failure. Results from Nile's Phase Ib and Phase IIa trials are expected to be available in 2008.

About CD-NP

CD-NP is a novel chimeric natriuretic peptide in clinical development for an initial indication of acute decompensated heart failure (ADHF). CD-NP was rationally designed by scientists at the Mayo Clinic's cardio-renal research labs. Current therapies for ADHF, including B-type natriuretic peptide, have been associated with favorable pharmacologic effects, but have also been associated with hypotension and decreased renal function which limit their utility in clinical practice. CD-NP was designed to preserve the favorable effects of current therapies while preventing or attenuating the hypotensive response, and enhancing or preserving renal function.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure; 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties; and CU-NP, a novel rationally designed natriuretic peptide. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile's product development, fu
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014 Breckenridge Pharmaceutical, Inc. announced ... with MSN Laboratories Pvt. Ltd. ( Hyderabad, India ... commercialize several new ANDAs.  Under the terms of the ... exclusively to Breckenridge for the U.S. market, and Breckenridge ... Breckenridge and MSN have agreed to develop an oral ...
(Date:12/19/2014)... 2014 In today,s increasingly global marketplace ... to reflect the needs of a global marketplace ... the needs of key stakeholders while recognizing regional ... According to recent research by benchmarking firm, Best ... companies averaged more than $100,000 in annual spending ...
(Date:12/19/2014)... -- Monarch America Inc. (OTCQB: CANK) ("Monarch America" or the ... this review of the Company,s recent achievements and strategic ... this past year, we achieved many of our early ... say that Monarch America is in a stronger and ... stated Eric Hagen , CEO of Monarch America ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Building a Best-in-Class Pharma Global Brand Website 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3
(Date:12/21/2014)... new collection of 2015 spring wedding dresses was released ... in this collection, and all of them are designed ... promises to provide the most fashionable designs to its ... trends come and go. If ladies have any questions ... ready to assist. , “These new models can ...
(Date:12/21/2014)... HealthDay Reporter FRIDAY, Dec. 19, ... addictive than traditional cigarettes, new research finds. Even ... cigarettes, thousands of ex-smokers said they have fewer cravings and ... need to smoke, researchers reported. "The pattern ... e-cig use than for tobacco use," said lead researcher Jonathan ...
(Date:12/21/2014)... 2014 The number of Mirena lawsuits ... litigation underway in New Jersey, Bernstein Liebhard LLP reports. ... claims involving the birth control IUD have now been ... filed by women who allege spontaneous migration of the ... perforations and other complications they were inadequately warned about ...
(Date:12/21/2014)... California (PRWEB) December 21, 2014 Serious ... search for Vintage 1967 Jm Morrison and the Doors International ... posters. This would also be the only time that ... concert was on Nov. 25, 1967. According to Hawley, ... D.C. They did play the Alexandria Roller Rink earlier ...
(Date:12/21/2014)... December 21, 2014 Over the past ... issues in hundreds of emergency departments across the nation, ... findings have been translated into an innovative suite of ... correct deficiencies and enhance the patient experience. , ... physician staffing and management services for hospitals, announced the ...
Breaking Medicine News(10 mins):Health News:2015 Spring Wedding Dresses From AngelWeddingDress Just Released 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2
... Boston. MA--The National Institute of Allergy and Infectious ... have awarded $5 million to an interdisciplinary group ... on Antibiotic Resistance." Headed by Michael S. Gilmore, ... Schepens Professor of Ophthalmology [Department of Microbiology and ...
... disease in study , TUESDAY, Oct. 13 (HealthDay ... use their imagination to reduce their pain, new study ... 6 to 15 years, with functional abdominal pain, which ... All the children received standard medical care, but 19 ...
... Oct. 13 Solta Medical, Inc. (Nasdaq: SLTM ... today announced the appointment of Jeffrey C. Nardoci, as ... more than 19 years of experience in marketing and ... goods markets. At Solta Medical, he will focus ...
... Human Services Grant to Fund Medical Assistance /MinnesotaCare Outreach ... PAUL, Minn., Oct. 13 Portico Healthnet, a non-profit ... coverage for health care services, has been awarded more ... Human Services (HHS) to launch the Minnesota Coalition for ...
... Calif., Oct. 13 The National Association of ... association for people working as healthcare and patient ... 14-15 at the University of California, Berkeley Clark ... topics ranging from best practices for advocacy decision-making ...
... that non-invasive ventilation be avoided during an infectious outbreak, ... http://www.cmaj.ca/embargo/cmaj081987.pdf ) in CMAJ ( Canadian ... it should be used expeditiously in this setting. ... the lungs of patients in respiratory failure, rather than ...
Cached Medicine News:Health News:New effort to battle antibiotic resistance rallies researchers throughout Harvard University 2Health News:Soothing Imagery May Help Rid Some Kids of Stomach Pain 2Health News:Solta Medical, Inc. Appoints Jeffrey Nardoci Vice President of Global Marketing 2Health News:Portico Healthnet Awarded $988K to Launch MN Coalition for Kids Health Coverage 2Health News:First Annual Conference of National Association of Healthcare Advocacy Consultants (NAHAC) to Be Held Nov. 14-15; Board of Directors Announced 2Health News:Should noninvasive ventilation be considered a high-risk procedure during an epidemic? 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: